Curis, Inc. (NASDAQ: CRIS), a drug development company, is focused on utilizing its innovative signaling pathway drug technologies to discover new targeting small molecule drug candidates for cancer. Through the expansion of its drug development efforts in the field of cancer, the company is building upon its previous experiences in targeting signaling pathways to develop next generation targeted cancer therapies. For further information, visit the Company’s web site at www.curis.com.
- 17 years ago
QualityStocks
Curis, Inc. (NASDAQ: CRIS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Launches 12-Month AI-Driven Marketing Campaign With AGORACOM
LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) announced a 12-month online marketing campaign with…
-
QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Strengthens Balance Sheet with Full Conversion of $13.3 Million Notes
Datavault AI (NASDAQ: DVLT), a pioneer in AI-driven data monetization, announced the full conversion of…
-
Nightfood Holdings Inc. (NGTF) Offering a Portfolio of AI-Powered Robots Designed to Streamline Operations and Enhance Efficiency
Nightfood Holdings has a lineup of AI-powered robots to streamline operations across industries, weaving technology…